Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24364222 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAMEN1KMT2APRCP | |
| SCHEMBL29081358 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAMEN1KMT2APRCP | |
| SCHEMBL29081355 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAMEN1KMT2APRCP | |
| SCHEMBL30469672 | 0.83 | TDP1 (0.38) | SMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL29324205 | 0.83 | TDP1 (0.38) | SMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL30470609 | 0.83 | ALDH1A1 (0.46) | SMN1; SMN2LMNAALDH1A1BRD4MAPT | |
| SCHEMBL29081223 | 0.83 | TDP1 (0.38) | SMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL29081225 | 0.83 | TDP1 (0.38) | SMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL29081943 | 0.83 | ALDH1A1 (0.46) | SMN1; SMN2LMNAALDH1A1BRD4MAPT | |
| SCHEMBL29081944 | 0.83 | ALDH1A1 (0.46) | SMN1; SMN2LMNAALDH1A1BRD4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SMN1; SMN2 1943/4885LMNA 1976/4885MEN1 142/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SMN1; SMN2 1943/4885LMNA 1976/4885MEN1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.